⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

Official Title: A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease

Study ID: NCT00528424

Interventions

AA4500

Study Description

Brief Summary: Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857 (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less, the cord affecting that joint received less than three injections of AA4500, or they had other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option to receive up to five injections of AA4500 in this extension study. Subjects requiring further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each injection, with injections separated by four weeks. Follow-up visits for the determination of efficacy and safety were conducted on Day 90, Month 6, and Month 9. This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

100 UCLA Medical Plaza, Suite 305, Los Angeles, California, United States

Hand Surgery Clinic, Palo Alto, California, United States

Hand Surgery Associates, PC, Denver, Colorado, United States

The Hand and Upper Extremity Center of Georgia, P.C., Atlanta, Georgia, United States

Rockford Orthopedic Associates, Ltd., Rockford, Illinois, United States

The Indiana Hand Center, Indianapolis, Indiana, United States

Brigham and Women's Hospital, Department of Orthopedic Surgery, Boston, Massachusetts, United States

Newton-Wellesley Hospital, Newton, Massachusetts, United States

TRIA Orthopaedic Center, Minneapolis, Minnesota, United States

Hospital for Special Surgery, New York, New York, United States

SUNY Stony Brook - Department of Orthopedics, Stony Brook, New York, United States

Health Research Institute, Oklahoma City, Oklahoma, United States

Hand Microsurgery & Reconstructive Orthopaedics, Erie, Pennsylvania, United States

University Orthopedics Center, State College, Pennsylvania, United States

Department of Orthopaedics, Brown University, Rhode Island Hospital, Providence, Rhode Island, United States

Contact Details

Name: Veronica Urdaneta, MD

Affiliation: Endo Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: